AstraZeneca rolls out at-home service for FluMist nasal flu vaccine

AstraZeneca (LSE: AZN) has launched FluMist Home, the first US Food and Drug Administration (FDA)-approved influenza vaccine program that allows self- or caregiver administration. FluMist (influenza vaccine live, intranasal) can now be delivered directly to households, making it the first seasonal flu shot available without a trip to the clinic or pharmacy.

Company executives said the new option is designed to make flu protection more convenient. “The launch of FluMist Home is a transformational moment in the evolution of influenza protection, bringing a simple and accessible option directly into the hands of consumers,” said Joris Silon, AstraZeneca’s US country president.

The FDA first approved FluMist in 2003. In 2024, regulators cleared its use for self-administration by adults aged 18 to 49, or by caregivers for children aged 2 to 17. Eligible individuals can order online by completing a medical questionnaire, which is reviewed by a licensed provider before the vaccine is shipped in cold storage.